Psoriasis affects about 3% of U.S. adults. Dr. Kathryn Kline explains the symptoms, types, causes, and the newest 2026 treatments — including the first oral IL-23 inhibitor.
By Dr. Kathryn Kline, MD · Board-Certified Family Medicine Physician (ABFM) · Published 2026-07-06 · Updated 2026-07-06
Psoriasis is a chronic autoimmune disease that causes the immune system to accelerate skin cell growth, leading to thick, scaly patches on the skin. It affects about 3% of U.S. adults, is not contagious, and can usually be managed with topical medications, phototherapy, oral drugs, or biologic therapies depending on severity.
Right now, somewhere beneath the surface of your skin, your immune system may be waging a quiet war against your own body. In psoriasis, that war becomes visible: your skin cells multiply up to ten times faster than normal, piling up into thick, scaly patches that itch, crack, and sometimes bleed. Approximately 7.5 million American adults — about 3% of the U.S. population — live with psoriasis, making it one of the most common immune-mediated skin conditions in the country. Yet most people with psoriasis wait years before getting an accurate diagnosis, and many never learn that the symptoms go far deeper than skin.
Psoriasis is not just a rash. It is a chronic, systemic inflammatory disease linked to cardiovascular disease, metabolic syndrome, [depression](/blog/depression-most-common-condition-doctor-can-treat), and joint destruction. The good news: treatment has never been better. From topical therapies your family doctor can prescribe today to the first-ever oral IL-23 inhibitor approved by the FDA in March 2026, the options for achieving clear or nearly clear skin are expanding rapidly. And much of psoriasis management — including diagnosis, medication adjustments, and mental health screening — can happen over a telehealth visit from home.
No. Psoriasis is an immune-mediated condition, not an infection. You cannot catch psoriasis from touching someone, sharing a pool, or any other form of contact. It is caused by your own immune system attacking healthy skin cells.
Most cases of mild to moderate psoriasis — which represent the majority of cases — can be effectively diagnosed and managed by a family medicine physician using topical corticosteroids, vitamin D analogues, and other first-line treatments. Your family doctor may refer you to a dermatologist if your psoriasis is severe, covers more than 10% of your body, or does not respond to initial treatment.
Psoriasis is a chronic condition, meaning the underlying immune dysfunction persists even when your skin is clear. However, many people achieve long periods of remission — months or even years — with proper treatment. With the newest medications, including biologic therapies and the recently approved oral IL-23 inhibitor icotrokinra, more patients than ever are achieving clear or nearly clear skin.
Yes, in most cases. Psoriasis is diagnosed clinically based on the appearance and distribution of skin lesions, combined with your medical history. A telehealth visit with clear photographs of your skin is often sufficient for diagnosis and to begin treatment. A biopsy is only needed in ambiguous cases.
The evidence supports a Mediterranean-style diet (rich in fish, olive oil, fruits, and vegetables) and weight management as beneficial adjuncts to medical treatment. Obesity worsens psoriasis severity and reduces treatment effectiveness. However, no specific 'psoriasis diet' has been proven to cure or replace medical treatment.
Icotrokinra (brand name Icotyde), approved by the FDA in March 2026, is the first oral IL-23 receptor antagonist for moderate-to-severe plaque psoriasis. It is a once-daily pill that achieved clear or almost clear skin in approximately 70% of patients in clinical trials, with a safety profile similar to placebo.